What You Should Know:
DarioHealth raises $28M in institutional financing
intended to finance growth of their digital therapeutics B2B market share with
employers, health insurance plans, and healthcare providers.
The company sold 2,969,266 shares of common stock and, to
certain investors in lieu thereof, pre-funded warrants to purchase 824,689
shares of common stock at an exercise price of $0.0001 per share.
DarioHealth Corp.
(Nasdaq: DRIO), a pioneer in the global digital therapeutics
Read More
Digital Therapeutics | Digital Health | Evidence-Based Therapeutics Interventions
DarioHealth, Williams Medical Partner to Expand Digital Therapeutics Platform Across the UK and Ireland
What You Should Know:
- Dario Health enters strategic partnership with Williams
Medical marking its expansion into the UK remote patient monitoring market across
the UK and Ireland.
- Williams Medical is the leading provider of medical
goods and services to primary care in the UK, and this agreement supports both
companies' commitment to drive growth and deliver innovative solutions to
frontline healthcare.
DarioHealth Corp., a
pioneer in the global digital therapeutics market,
Read More
10 Healthcare Innovations That Can Reduce Total Disease Burden 6-10% by 2040
What You Should Know:
- 40 percent of
the global disease burden could be addressed with known interventions, but that
leaves 60 percent unaddressed.
- As part of the recent McKinsey report Prioritizing
health: A prescription for prosperity, the McKinsey Global Institute identified
ten promising innovations that can reduce total disease burden 6-10% by 2040.
- By identifying and estimating the potential scope of
innovations in the pipeline, we find that these technologies could
Read More
Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics
What You Should Know:
- Repurpose.AI, has partnered with Scripps Research to
discover drug candidates that may be repurposed to treat COVID-19.
- The partnership will leverage Repurpose.AI's ActivPred
AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic
digital chemistry engine, to discover drug candidates to treat COVID-19.
Scripps Research is
teaming up with Repurpose.AI, an AI
drug discovery company to develop COVID-19 therapeutics. The
Read More
Kaia Health Lands $26M to Expand AI-Driven Digital Therapeutics for MSK Conditions & COPD
What You Should Know:
- Digital therapeutics company Kaia Health raises $26M in
Series B funding to help grow its digital therapy solutions for musculoskeletal
(MSK) conditions, and expand into new conditions.
- The investment was led by Optum Ventures, Idinvest and
capital300, plus participation from Balderton Capital, Heartcore Capital and
Symphony Ventures, an investment partnership with world #1 golfer Rory McIlroy.
- Kaia Health’s smartphone-based
approach to managing chronic
Read More
5 Reasons Why Providers Need Electronic Support for Glycemic Management
It’s no secret hyperglycemia and hypoglycemia are associated with adverse outcomes in hospitalized patients. We’ve known for many years that hyperglycemia is widespread in the hospital, causes immune dysfunction, higher rates of infection, a longer length of hospital stay, complications, and even death.
Insulin has been the most effective therapy for hyperglycemia since it was first created almost 100 years ago, but it can also be dangerous if not managed properly. In fact, nearly 50% of all
Read More
Sharecare Acquires Evidence-Based Behavior Change Apps MindSciences
What You Should Know:
- Sharecare announced the acquisition of Boston-based MindSciences, an evidence-based behavior change suite of apps focused on mental health (anxiety, stress management), smoking cessation, and weight loss/binge eating, and more.
- The acquisition rounds out Sharecare’s portfolio of mHealth-based therapeutic programs improving chronic disease risk and overall health outcomes by targeting varying aspects of well-being.
- Based on the work of Dr. Judson Brewer, now
Read More
The DNA Company Acquires AI Digital Therapeutics App for $30M to Form My Next Health
What You Should Know:
- DNA Company acquires AI-based digital therapeutics app My Pain Sensei (MPS) to form My Next Health and is building a COVID-19 risk assessment platform to help people understand their risks of developing serious COVID-19 complications.
- The acquisition combines functional genomics with conversational AI for patient self-management apps and disease tracking tools designed to inform clinician-patient interactions.
Leading functional genomics provider The
Read More
Biofourmis Acquires Digital Therapeutics Oncology Startup Gaido Health
What You Should Know:
- Boston-based digital therapeutics startup Biofourmis acquires LA-based Gaido Health from Takeda Pharmaceuticals, in a strategic deal that expands Biofourmis’ portfolio in the oncology space.
- Gaido Health—a digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm.
- With Gaido Health’s and Biofourmis’ dual focus on remote monitoring with wearables
Read More
What Health IT Thought Leaders Say HIMSS20 Would Have Focused On—If It Had Happened
What You Need to Know:
Health IT thought leaders share what HIMSS20 would have focused On—if It had happened.
- Hot topics include health IT to address COVID-19; artificial intelligence; EHR interoperability and usability; and more.
–Kuldeep Singh Rajput, CEO of Biofourmis, Boston, Mass., which provides digital therapeutics that power personalized predictive care
“Remote monitoring platforms and clinical-grade wearables combined with artificial intelligence [AI]-based
Read More
